Related Experiment Video
Updated: Aug 14, 2026

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
Published on: January 26, 2019
Rotavirus vaccine: early introduction in Latin America-risks and benefits
Jimena Pérez-Vargas1, Pavel Isa, Susana López
1Departamento de Genética del Desarrollo y Fisiología Molecular, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Morelos, México.
Insights
Rotavirus vaccines aim to prevent severe childhood gastroenteritis, a major cause of death. This review examines rotavirus vaccine development, including safety concerns like intussusception, and the introduction of Rotarix in Mexico.
Area of Science:
- Pediatrics
- Vaccinology
- Gastroenterology
Background:
- Rotavirus infection causes severe gastroenteritis in young children globally, resulting in approximately 600,000 deaths annually.
- An early rotavirus vaccine, RotaShield, was withdrawn due to intussusception concerns, prompting the development of new vaccine candidates.
- Rotavirus vaccines are critical for reducing childhood mortality and morbidity from gastroenteritis.
Purpose of the Study:
- To review the background of rotavirus vaccine development.
- To evaluate different rotavirus vaccine candidates in clinical trials.
- To discuss the association between rotavirus vaccination and intussusception.
- To analyze the benefits and risks of introducing Rotarix in Latin America, specifically Mexico.
Main Methods:
- Literature review of rotavirus vaccine development.
- Analysis of clinical trial data for rotavirus vaccine candidates.
- Examination of epidemiological data on intussusception and rotavirus vaccination.
- Assessment of public health policy regarding rotavirus vaccine introduction.
Main Results:
- Several rotavirus vaccine candidates are in late-stage clinical trials.
- The association between rotavirus vaccination and intussusception requires careful monitoring.
- Rotarix has been licensed for use in Mexico, marking a significant step in rotavirus prevention in the region.
Conclusions:
- The development of safe and effective rotavirus vaccines is crucial for global child health.
- Careful risk-benefit assessment is necessary for the rapid implementation of new vaccines like Rotarix.
- Continued surveillance for adverse events, such as intussusception, is essential post-licensure.
Abstract:
Rotavirus infection is the cause of severe gastroenteritis of young children worldwide, leading to an estimate of 600,000 deaths a year. Efforts to develop an effective and safe vaccine resulted in licensing in 1998 of a live oral vaccine (RotaShield) that was withdrawn less than 1 year later when reports of cases of intussusception were linked to its application. This led to development of new rotavirus vaccine candidates that are currently in late phase III clinical trials. One of these vaccines, GlaxoSmithKline's Rotarix, was licensed in July 2004 to be used in Mexico. This review describes the general background for rotavirus vaccine development, the different vaccine candidates that have been tested or are currently being evaluated, the association of rotavirus vaccination with the bowel blockage known as intussuception, and discusses the benefits and risks of the fast-track introduction of Rotarix in Latin America, and particularly in Mexico.
Related Concept Videos
Respiratory Syncytial Virus Disease
Poliomyelitis
Vaccinations
Vaccines
Bacterial Gastroenteritis
Viral Hepatitis I: Introduction
